Patent SG-11201810927Q-A (SG)
Title: Pd-l1-specific antibodies and methods of using the same
Inventor: BELK JONATHAN
IPC: A61K39/395
Filed: 2017-06-28
Abstract: CTINegative control mAb Clinical control mAb IC50 0.4909 0.1941 - 0.0 60000 40000 20000 0 0.001 0.01 0.1 1 10 I ogiAntagonisq, ugeml -J 100 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 January 2018 (04.01.2018) W I PO I PCT mu °million °nolo olon imio (10) International Publication Number WO 2018/005682 A2 (51) International Patent Classification: C07K 16/28 (2006.01) A61K 45/06 (2006.01) (21) International Application Number: PCT/US2017/039810 (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: without international search report and to be republished upon receipt of that report (Rule 48.2(g)) 28 June 2017 (28.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/356,105 29 June 2016 (29.06.2016) US (71) Applicant: CHECKPOINT THERAPEUTICS, INC. [US/US]; 2 Gansevoort Street, 9th Floor, New York, NY 10014 (US). (72) Inventors: BELK, Jonathan; c/o Adimab, LLC, 7 Lucent Drive, Lebanon, NH 03766 (US). SHARKEY, Nathan, J.; c/o Adimab, LLC, 7 Lucent Drive, Lebanon, NH 03766 (US). GORELIK, Leonid; 69 Winston Road, Newton, MA 02459 (US). (74) Agent: VILLACORTA, Gilberto, M. et al.; Foley & Lard- ner LLP, 3000 K Street NW, Suite 600, Washington, DC 20007 (US). = (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, W O 20 18/005 68 2 A2 (54) Title: PD-Ll-SPECIFIC ANTIBODIES AND METHODS OF USING THE SAME is Clinical control mAb CTI-048 A Negative control mAb FIGURE 5 (57) : The present disclosure relates generally to antibodies and functional binding fragments thereof that bind to programmed death-ligand 1 (PD-L1). In particular, the disclosed antibodies and fragments bind to human PD-Ll and comprise novel complementary determining regions (CDRs) also disclosed herein. Finally, the present disclosure relates to administering the disclosed antibodies and fragments to subjects with cancer, thereby treating or slowing the progression or proliferation of the cancer.